-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 4th, the Shanxi Provincial Pharmaceutical Equipment Centralized Bidding and Purchasing Center issued the "Notice on Supplementing the Online Purchase of Glimepiride Tablets by Shandong Xinhua Pharmaceutical Co.
, Ltd.
".
The document mentioned that inglimepiride tablets were originally The drug production management of the selected company is not standardized, and the production and sales of glimepiride are now suspended
.
The notice shows that there are serious defects in the plant maintenance, equipment cleaning, stability inspection, etc.
of the original selected glimepiride tablet, which does not meet the drug production management standards
.
At the same time, Shandong Xinhua Pharmaceutical's Glimepiride Tablets are eligible to be listed in the province
.
It is understood that glimepiride tablets are the second batch of selected products for centralized drug procurement organized by the state.
The results of this batch of centralized procurement have been implemented in various places in April 2020
.
However, recently, the drug regulatory authority found in the unannounced inspection that the drugs of the original company selected for Glimepiride Tablets in Shanxi Province did not meet the specifications, so they made a decision to suspend production and sales and supplement the products of another company
.
In addition to Shanxi Province, on January 28 this year, the Guizhou Provincial Food and Drug Administration also released public information, suspending the production and sales of the above-mentioned non-compliant enterprises glimepiride tablets in accordance with the law, and further investigation and handling
.
In recent years, centralized procurement has become normalized.
For pharmaceutical companies, the successful entry of products into centralized procurement is beneficial to the market sales of products in the long run
.
However, pharmaceutical companies in centralized procurement also face major challenges in compliance with production and other aspects
.
In addition to the above-mentioned pharmaceutical companies, many selected pharmaceutical companies have been withdrawn from the selection qualification in recent years
.
The main reasons include supply interruption and quality problems
.
For example, on February 16, Danzhou City issued an article on the forwarding of the "Hainan Provincial Medical Security Bureau on Doing a Good Job in the Shortage Drug Alliance to Ensure Supply, Stable Price, and Procurement of Posterior Pituitary Injection (1ml: 61U) for Selected Enterprises to Replace Work.
Notice"
.
The content of the notice shows that since the posterior pituitary injection (Iml: 61U) of the original selected enterprise cannot be supplied normally in the short term, in order to ensure clinical use, another selected enterprise, Anhui Hongye Pharmaceutical Co.
, Ltd.
, will replace the supply.
.
In August 2021, the State Organization of the Joint Drug Procurement Office issued an announcement on the inclusion of a pharmaceutical company on the list of violations
.
The announcement pointed out that the pharmaceutical company was selected as the third batch of Ibuprofen Sustained-Release Capsules for the centralized procurement of drugs organized by the state, but it failed to supply the agreed procurement volume in Shandong Province according to the agreement.
The situation has not improved, and the company proposed to give up its eligibility for election on August 11, 2021
.
It is worth mentioning that the cessation of confession is not only as simple as being removed from the selection qualification.
According to relevant regulations, after the collective deliberation of the member units of the National Organization Drug Joint Procurement Office, it was decided to list the above-mentioned ibuprofen sustained-release capsule production enterprises.
The "violation list" will cancel the enterprise's application qualification for participating in the centralized drug procurement activities organized by the state from August 11, 2021 to May 10, 2022
.
In this regard, industry insiders said that the inclusion of pharmaceutical companies on the list of violations is not good news, because companies may lose a lot of market share during the penalty period, which will have a certain impact on the company's profits
.
At present, the seventh batch of centralized procurement is already in the air
.
For pharmaceutical companies, on the one hand, they need to be prepared to enter centralized procurement, and on the other hand, they also need to find a balance between centralized procurement
.
Due to the "one-time purchase for a lifetime", pharmaceutical companies need to do a good job of ensuring quality and quantity after the centralized purchase.
Otherwise, problems such as interruption of supply and quality are likely to affect the clinical treatment of drugs and thus affect the treatment of patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
, Ltd.
".
The document mentioned that inglimepiride tablets were originally The drug production management of the selected company is not standardized, and the production and sales of glimepiride are now suspended
.
The notice shows that there are serious defects in the plant maintenance, equipment cleaning, stability inspection, etc.
of the original selected glimepiride tablet, which does not meet the drug production management standards
.
At the same time, Shandong Xinhua Pharmaceutical's Glimepiride Tablets are eligible to be listed in the province
.
It is understood that glimepiride tablets are the second batch of selected products for centralized drug procurement organized by the state.
The results of this batch of centralized procurement have been implemented in various places in April 2020
.
However, recently, the drug regulatory authority found in the unannounced inspection that the drugs of the original company selected for Glimepiride Tablets in Shanxi Province did not meet the specifications, so they made a decision to suspend production and sales and supplement the products of another company
.
In addition to Shanxi Province, on January 28 this year, the Guizhou Provincial Food and Drug Administration also released public information, suspending the production and sales of the above-mentioned non-compliant enterprises glimepiride tablets in accordance with the law, and further investigation and handling
.
In recent years, centralized procurement has become normalized.
For pharmaceutical companies, the successful entry of products into centralized procurement is beneficial to the market sales of products in the long run
.
However, pharmaceutical companies in centralized procurement also face major challenges in compliance with production and other aspects
.
In addition to the above-mentioned pharmaceutical companies, many selected pharmaceutical companies have been withdrawn from the selection qualification in recent years
.
The main reasons include supply interruption and quality problems
.
For example, on February 16, Danzhou City issued an article on the forwarding of the "Hainan Provincial Medical Security Bureau on Doing a Good Job in the Shortage Drug Alliance to Ensure Supply, Stable Price, and Procurement of Posterior Pituitary Injection (1ml: 61U) for Selected Enterprises to Replace Work.
Notice"
.
The content of the notice shows that since the posterior pituitary injection (Iml: 61U) of the original selected enterprise cannot be supplied normally in the short term, in order to ensure clinical use, another selected enterprise, Anhui Hongye Pharmaceutical Co.
, Ltd.
, will replace the supply.
.
In August 2021, the State Organization of the Joint Drug Procurement Office issued an announcement on the inclusion of a pharmaceutical company on the list of violations
.
The announcement pointed out that the pharmaceutical company was selected as the third batch of Ibuprofen Sustained-Release Capsules for the centralized procurement of drugs organized by the state, but it failed to supply the agreed procurement volume in Shandong Province according to the agreement.
The situation has not improved, and the company proposed to give up its eligibility for election on August 11, 2021
.
It is worth mentioning that the cessation of confession is not only as simple as being removed from the selection qualification.
According to relevant regulations, after the collective deliberation of the member units of the National Organization Drug Joint Procurement Office, it was decided to list the above-mentioned ibuprofen sustained-release capsule production enterprises.
The "violation list" will cancel the enterprise's application qualification for participating in the centralized drug procurement activities organized by the state from August 11, 2021 to May 10, 2022
.
In this regard, industry insiders said that the inclusion of pharmaceutical companies on the list of violations is not good news, because companies may lose a lot of market share during the penalty period, which will have a certain impact on the company's profits
.
At present, the seventh batch of centralized procurement is already in the air
.
For pharmaceutical companies, on the one hand, they need to be prepared to enter centralized procurement, and on the other hand, they also need to find a balance between centralized procurement
.
Due to the "one-time purchase for a lifetime", pharmaceutical companies need to do a good job of ensuring quality and quantity after the centralized purchase.
Otherwise, problems such as interruption of supply and quality are likely to affect the clinical treatment of drugs and thus affect the treatment of patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
